# Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus

> **NCT02995005** · PHASE1,PHASE2 · COMPLETED · sponsor: **Johns Hopkins Bloomberg School of Public Health** · enrollment: 98 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate

## Key facts

- **NCT ID:** NCT02995005
- **Lead sponsor:** Johns Hopkins Bloomberg School of Public Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-24
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02995005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02995005, "Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02995005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*